Valeant Pharmaceuticals International, Inc.

Form 4/A April 11, 2011

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB APPROVAL

Number: 3235-0287

Expires: January 31, 2005
Estimated average

burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5

SECURITIESFiled pursuant to Section 16(a) of the Securities Exchange Act of 1934,

obligations may continue.

See Instruction

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * INGRAM ROBERT ALEXANDER			2. Issuer Name and Ticker or Trading Symbol Valeant Pharmaceuticals International, Inc. [VRX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O 7150 MI	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 09/28/2010	_X_ Director 10% Owner Officer (give title below) Other (specify below)			
MISSISSAU	(Street) GA, A6 L5	N 8M5	4. If Amendment, Date Original Filed(Month/Day/Year) 09/30/2010	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acc	quired, Disposed of, or Beneficially Owned			

	Tubio 1 1101 Zeri unive Securities required, 215 posecu et, or Zeriericking et inte								
1.Title of Security	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if	3. Transactio	4. Securitie on(A) or Disp	•		5. Amount of Securities	6. Ownership Form: Direct	7. Nature of Indirect
(Instr. 3)		any (Month/Day/Year)		(Instr. 3, 4 and 5)		Beneficially Owned	(D) or Indirect (I)	Beneficial Ownership	
		(Mining Edy, 1 car)	(Instr. 8)		Following		(Instr. 4)	(Instr. 4)	
					(A) or		Reported Transaction(s)		
			Code V	Amount	(D)	Price	(Instr. 3 and 4)		
Common Stock, no par value	09/28/2010		A	210,449 (1) (2)	A	\$0	210,449 (2)	D	
Common Stock, no par value	09/28/2010		A	9,872 (3)	A	\$0	220,321 (2)	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 4/A

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	f 2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exer	cisable and	7. Titl	le and	8. Price of	9. Nu
Derivativ	e Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orNumber	Expiration D	ate	Amou	ınt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	/Year)	Under	rlying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativ	e		Secur	ities	(Instr. 5)	Bene
	Derivative				Securities	S		(Instr.	. 3 and 4)		Own
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									A		
									Amount		
						Date	Expiration	T:41-	or Namel		
						Exercisable	Date		Number		
				C-1- V	(A) (D)				of		
				Code v	(A) (D)				Shares		

Reporting Owners

Relationships

Reporting Owner Name / Address

Officer Director Other Owner

INGRAM ROBERT ALEXANDER C/O 7150 MISSISSAUGA ROAD MISSISSAUGA, A6 L5N 8M5

X

Signatures

By: Angie Palmer for Robert A. Ingram

04/11/2011

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents restricted share units received upon conversion of a portion of the reporting person's Valeant Pharmaceuticals International ("old Valeant") restricted stock units that were held prior to the merger between the issuer (formerly known as Biovail Corporation) and

- (1) old Valeant (the "Merger"), in accordance with the terms of the merger agreement between the issuer and, amongst others, old Valeant. The restricted share units can be settled only in common shares of the issuer. The fair market value of old Valeant on the day prior to the effective date of the Merger was \$63.25 per share.
- (2) This amendment is being filed to correct the number of restricted share units that were reported in the original filing.
- Represents common shares received upon conversion of the reporting person's remaining old Valeant restricted stock units that were held (3) prior to the Merger (i.e. those that were not converted into restricted share units as described in Footnote 1), in accordance with the terms of the merger agreement. The fair market value of old Valeant on the day prior to the effective date of the Merger was \$63.25 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2